Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ED90 of intravenous remimazolam for CT sedation in children with non-cyanotic congenital heart disease
ChiCTR2500098720Phase 4Completed
- Sponsor
- Shanghai Children's Medical Center
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of remimazolam in Cardiovascular Malformation (CVM), sponsored by Shanghai Children's Medical Center. Primary endpoints: Ramsay sedation score and Heart rate. Started Mar 2025; status: completed.
02
Drugs
remimazolam
03
Conditions
Cardiovascular Malformation (CVM)
Beyond the preview
Go deeper on ChiCTR2500098720.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500098720.